These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33887465)

  • 1. Time-To-Event Data: An Overview and Analysis Considerations.
    Le-Rademacher J; Wang X
    J Thorac Oncol; 2021 Jul; 16(7):1067-1074. PubMed ID: 33887465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Practical Overview and Reporting Strategies for Statistical Analysis of Survival Studies.
    Dey T; Mukherjee A; Chakraborty S
    Chest; 2020 Jul; 158(1S):S39-S48. PubMed ID: 32658651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Proper Use and Reporting of Survival Analysis and Cox Regression.
    Su PF; Lin CK; Hung JY; Lee JS
    World Neurosurg; 2022 May; 161():303-309. PubMed ID: 35505548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival Analysis and Interpretation of Time-to-Event Data: The Tortoise and the Hare.
    Schober P; Vetter TR
    Anesth Analg; 2018 Sep; 127(3):792-798. PubMed ID: 30015653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Considerations for analysis of time-to-event outcomes subject to competing risks in veterinary clinical studies.
    Oyama MA; Shaw PA; Ellenberg SS
    J Vet Cardiol; 2018 Jun; 20(3):143-153. PubMed ID: 29680637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of Survival Time and Other Event Times - What Does the Surgeon Need to Know?].
    Kropf S; Meyer F; Glimm E
    Zentralbl Chir; 2016 Aug; 141(4):383-9. PubMed ID: 25333520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of gastric cancer survival: using an artificial hierarchical neural network.
    Amiri Z; Mohammad K; Mahmoudi M; Zeraati H; Fotouhi A
    Pak J Biol Sci; 2008 Apr; 11(8):1076-84. PubMed ID: 18819544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competing risks analysis of time-to-event data for cardiovascular surgeons.
    Staffa SJ; Zurakowski D
    J Thorac Cardiovasc Surg; 2020 Jun; 159(6):2459-2466.e5. PubMed ID: 31866080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Overview of Introductory and Advanced Survival Analysis Methods in Clinical Applications: Where Have we Come so far?
    Beis G; Iliopoulos A; Papasotiriou I
    Anticancer Res; 2024 Feb; 44(2):471-487. PubMed ID: 38307572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical issues and methods in designing and analyzing survival studies.
    Perera M; Dwivedi AK
    Cancer Rep (Hoboken); 2020 Aug; 3(4):e1176. PubMed ID: 32794639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the Cox model to the Fine-Gray model for survival analyses of re-fracture rates.
    Nolan EK; Chen HY
    Arch Osteoporos; 2020 Jun; 15(1):86. PubMed ID: 32519193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
    Huang B; Kuan PF
    Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged progression-free survival and overall survival are associated with diabetes mellitus but inversely associated with levels of blood glucose in patients with lung cancer.
    Wang NF; Tang HM; Liu FL; Hong QY
    Chin Med J (Engl); 2020 Apr; 133(7):786-791. PubMed ID: 32195672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients.
    de Glas NA; Kiderlen M; Vandenbroucke JP; de Craen AJ; Portielje JE; van de Velde CJ; Liefers GJ; Bastiaannet E; Le Cessie S
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26614095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introduction to the Analysis of Survival Data in the Presence of Competing Risks.
    Austin PC; Lee DS; Fine JP
    Circulation; 2016 Feb; 133(6):601-9. PubMed ID: 26858290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peritonitis-free survival in peritoneal dialysis: an update taking competing risks into account.
    Evans DW; Ryckelynck JP; Fabre E; Verger C
    Nephrol Dial Transplant; 2010 Jul; 25(7):2315-22. PubMed ID: 20103502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measures of follow-up in time-to-event studies: Why provide them and what should they be?
    Betensky RA
    Clin Trials; 2015 Aug; 12(4):403-8. PubMed ID: 26025565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the importance of accounting for competing risks in pediatric cancer trials designed to delay or avoid radiotherapy: I. Basic concepts and first analyses.
    Tai BC; Grundy RG; Machin D
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1493-9. PubMed ID: 19577860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Competing risk bias was common in Kaplan-Meier risk estimates published in prominent medical journals.
    van Walraven C; McAlister FA
    J Clin Epidemiol; 2016 Jan; 69():170-3.e8. PubMed ID: 26232083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.